GLP-1 and obesity drug stocks
Sellers or developers of GLP-1 and other obesity drugs, like Ozempic, Wegovy, and Zepbound.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Eli Lilly & Co. in the news today
Eli Lilly Agrees to Buy Calytrix Bio for Up to $1.5 Billion, Bloomberg reports.
GLP-1 and obesity drug stocks, ranked by Quality Score
| Stock | Price | Quality Score | |||
|---|---|---|---|---|---|
| $1,431.67 | |||||
| $462.32 | |||||
| $107.48 | |||||
| $41.60 | |||||
| $1.56 | |||||
| $3.38 | |||||
| $18.57 | |||||
| $12.57 | |||||
| $53.12 | |||||
| $26.80 | |||||
| $2.87 | |||||
| $18.56 | |||||
| $1.85 | |||||
Why GLP-1 and obesity drug stocks are down this week
GLP-1 and obesity drug stocks fell a median 7.6% since the close on Nov 9 (13 stocks); the S&P 500 fell 1.7%.
What moved them
- No single story: 11 of 13 fell with the market this week.
What moved today
GLP-1 and obesity drug stocks are down 5.3% on average, 13 of 13 down.
What moves GLP-1 and obesity drug stocks
Trial results, FDA decisions, and prices drive the news.
- Trial results and FDA decisions
- Prices, and whether Medicare and insurers pay
- Prescription numbers each quarter
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
Questions about GLP-1 and obesity drug stocks
Why are GLP-1 and obesity drug stocks down this week?
GLP-1 and obesity drug stocks fell a median 7.6% since the close on Nov 9 (13 stocks); the S&P 500 fell 1.7%. No single story: 11 of 13 fell with the market this week.
Which GLP-1 and obesity drug stocks fell most this week?
Altimmune (ALT) fell 26%, Hims & Hers Health (HIMS) fell 19%, and Wave Life Sciences (WVE) fell 18%.
How many GLP-1 and obesity drug stocks are there?
This list has 13. A stock is on it when it sells or is developing a GLP-1 drug or another obesity medicine, or sells GLP-1 prescriptions as a main line, and its annual report says so. Left out: device makers whose parts go into the pens, supplement sellers, and companies whose obesity program is a minor one.
Which GLP-1 and obesity drug stocks does Breakaway rank highest?
Eli Lilly (LLY) 19, Amgen (AMGN) 17, and Rhythm Pharmaceuticals (RYTM) 8, the highest Quality Scores of the 13. Breakaway ranks every stock by its Quality Score, which reads each company's numbers and its chart; the ranking is information, not advice, and each stock's page shows the reasons behind its score.
Which GLP-1 and obesity drug stocks are under $5?
4 of the 13 traded under $5 at the prices on this page: Altimmune (ALT) at $1.56, LifeMD (LFMD) at $1.85, Wave Life Sciences (WVE) at $2.87, and Corbus Pharmaceuticals Holdings (CRBP) at $3.38.
Which GLP-1 and obesity drug stocks pay a dividend?
3 of the 13 paid a regular cash dividend in the last 12 months: Eli Lilly (LLY), Amgen (AMGN), and Novo Nordisk (NVO).
Is there an ETF for GLP-1 and obesity drug stocks?
Yes, for one: the Amplify Weight Loss Drug & Treatment ETF (THNR) holds weight loss drug makers and their suppliers. This list is the companies themselves, each one ranked by its Quality Score.
Do these GLP-1 and obesity drug stocks trade in the US?
Yes. All 13 trade on US stock exchanges, in US dollars. One is a company from outside the US: Novo Nordisk (NVO).
Use this page
How to cite
Breakaway, GLP-1 and Obesity Drug Stocks List: 13 Companies, Ranked, Nov 16, 2026, getbreakaway.com/themes/glp-1
Journalists: email support@getbreakaway.com for the data behind this page.